Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC Zhou, C., Das Thakur, M., Srivastava, M. K., Zou, W., Xu, H., Ballinger, M., Felip, E., Wakelee, H., Altorki, N. K., Reck, M., Liersch, R., Kryzhanivska, A., Harada, M., Tanaka, H., Hamm, J., McCune, S., McNally, V., Bennett, E., Gitlitz, B., Novello, S. ELSEVIER. 2021: S1374
View details for DOI 10.1016/j.annonc.2021.10.018
View details for Web of Science ID 000731051400003